|1.||Vander Stichele, Robert H: 2 articles (01/2009 - 09/2008)|
|2.||Van Bortel, Luc M: 2 articles (01/2009 - 09/2008)|
|3.||de Backer, T L M: 2 articles (01/2008 - 01/2007)|
|4.||Bogaert, M: 2 articles (01/2008 - 01/2007)|
|5.||Vander Stichele, R: 2 articles (01/2008 - 01/2007)|
|6.||Wu, Simiao: 1 article (01/2015)|
|7.||He, Sha: 1 article (01/2015)|
|8.||Liu, Ming: 1 article (01/2015)|
|9.||Lin, Sen: 1 article (01/2015)|
|10.||Zeng, Quantao: 1 article (01/2015)|
12/01/2001 - "These findings suggest the therapeutic efficacy of buflomedil in diabetic subjects with intermittent claudication. "
01/01/2001 - "There is a lack evidence for the efficacy of buflomedil in intermittent claudication."
01/01/2001 - "There is little evidence available to evaluate the efficacy of buflomedil for intermittent claudication. "
01/01/2001 - "To evaluate the available evidence on the efficacy of buflomedil for intermittent claudication. "
02/12/2008 - "We performed an international, multicenter, randomized, double-blind, placebo-controlled trial to investigate whether long-term administration of oral buflomedil could reduce the rate of cardiovascular events in patients with intermittent claudication. "
|2.||Peripheral Arterial Disease
01/01/1982 - "Protective effects of buflomedil against exercise-induced reductions in regional erythrocyte deformability of patients with peripheral arterial disease."
02/12/2008 - "Buflomedil in peripheral arterial disease: trials and tribulations."
01/01/2015 - "Buflomedil is a vasoactive agent that has been used for peripheral arterial diseases. "
10/01/2008 - "Buflomedil reduced cardiovascular events in peripheral arterial disease."
01/01/1989 - "Buflomedil is a vasoactive agent widely used in the treatment of peripheral arterial disease. "
01/01/2015 - "We included randomised controlled trials (RCTs) that investigated the efficacy of buflomedil in people with acute ischaemic stroke. "
01/01/2015 - " one trial reported long-term death and disability, where stroke survivors in the buflomedil group had a lower risk of suffering 'death or disability' than those in the control group (200 participants, RR 0.71, 95% confidence interval (CI) 0.53 to 0.94). "
01/01/2015 - "Given these uncertainties, the data support the rationale for an adequately powered RCT of buflomedil in people with acute ischaemic stroke."
01/01/2015 - "There is insufficient evidence on the efficacy or safety of buflomedil to support its use for the treatment of acute ischaemic stroke. "
01/01/2015 - "To assess the efficacy and safety of buflomedil for the treatment of acute ischaemic stroke. "
|4.||Alzheimer Disease (Alzheimer's Disease)
05/01/1990 - "Tolerance of long-term buflomedil was assessed by compiling safety data (adverse effects, vital signs and clinical laboratory results) from three multicentre clinical trials in patients with intermittent claudication or Alzheimer's disease-type senile dementia. "
01/01/1985 - "Seventy-six patients took part in a randomized, comparative study of the efficacy of buflomedil hydrochloride and dihydrogenated ergot alkaloids in the treatment of senile dementia associated with cerebrovascular insufficiency. "
01/01/1985 - "In conclusion, buflomedil is as effective or more effective than dihydrogenated ergot alkaloids in the treatment of senile dementia associated with cerebrovascular insufficiency and could prove a valuable addition to long-term therapy if further studies support the trend shown in this study."
01/01/1985 - "The treatment of senile dementia associated with cerebrovascular insufficiency: a comparative study of buflomedil and dihydrogenated ergot alkaloids."
05/01/1987 - "In patients with symptoms presumed to be due to cerebrovascular insufficiencies and elderly patients with senile dementia, buflomedil 450 to 600 mg/day alleviated symptoms associated with impairment of cognitive and psychometric function and was significantly superior to placebo and slightly more effective than drugs such as cinnarizine, flunarizine and co-dergocrine mesylate. "
|5.||Peripheral Vascular Diseases (Peripheral Vascular Disease)
01/01/2013 - "Buflomedil is a vasoactive agent used to treat peripheral vascular disease. "
01/01/2008 - "Buflomedil is a vasoactive agent used to treat peripheral vascular disease. "
01/01/2007 - "Buflomedil is a vasoactive agent used to treat peripheral vascular disease. "
05/01/1996 - "Buflomedil (CAS 55837-25-7, Fonzylane) is a peripherally vasoactive drug which improves nutritional blood flow in ischaemic tissue of patients with peripheral vascular disease by the way of an increase of perfusion in the microcirculation. "
05/01/1992 - "The aim was to evaluate whether buflomedil (a drug used to treat peripheral vascular disease and which has a number of pharmacological actions potentially beneficial to dysfunctional myocardium) would preserve myocardial function after transient coronary artery occlusion followed by reperfusion. "
|8.||Vasodilator Agents (Vasodilators)